Activation of CYP2C9-mediated metabolism by a series of dapsone analogs: Kinetics and structural requirements

被引:37
|
作者
Hutzler, JM [1 ]
Kolwankar, D [1 ]
Hummel, MA [1 ]
Tracy, TS [1 ]
机构
[1] W Virginia Univ, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA
关键词
D O I
10.1124/dmd.30.11.1194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytochrome P450 2C9-mediated metabolism has been shown to be activated in the presence of the effector dapsone. However, it has yet to be established what effector structural features are necessary to activate CYP2C9 activity. To address this question, kinetic studies were conducted with nine analogs of dapsone containing various functional properties (three sulfone compounds, three carbonyl compounds, and three sulfonamide compounds), to examine the functional groups important for enzyme activation by the effector (dapsone). Results show that phenylsulfone (dapsone without the para-amino groups) activates flurbiprofen 4'-hydroxylation comparable to dapsone but inhibits naproxen demethylation. Meanwhile, p-tolylsulfone had little effect on flurbiprofen metabolism, but activated naproxen demethylation, albeit only at high concentrations. These substrate-dependent differences in effect suggest that naproxen has a different binding orientation compared with flurbiprofen. Perhaps most interesting is that replacement of only one amino group from dapsone with a nitro group (4-(4-nitrophenylsulfonyl)-aniline) resulted in substantial inhibition of flurbiprofen 4'-hydroxylation, suggesting that electronic effects may influence activation of this substrate. Other analogs either had minor or no effect on CYP2C9-mediated metabolism. Overall, it is apparent from these studies that a sulfone group in direct association with two benzene rings with para-electron-donating groups represents the most efficient activator of CYP2C9. However, the effects of these analogs appear to be concentration-and substrate-dependent, further complicating the prediction of these types of in vitro interactions.
引用
收藏
页码:1194 / 1200
页数:7
相关论文
共 50 条
  • [41] Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide
    Tirkkonen, T.
    Heikkila, P.
    Huupponen, R.
    Laine, K.
    JOURNAL OF INTERNAL MEDICINE, 2010, 268 (04) : 359 - 366
  • [42] Enzyme kinetics of valproic acid metabolism by human cDNA CYP2A6, CYP2B6, and CYP2C9*1
    Ho, PC
    Chang, TKH
    Abbott, FS
    DRUG METABOLISM REVIEWS, 2002, 34 : 112 - 112
  • [43] Coupling and uncoupling of CYP2C9 and its variants in metabolism of the atypical kinetics substrate naproxen
    Wei, L
    Locuson, CW
    Tracy, TS
    FASEB JOURNAL, 2006, 20 (04): : A263 - A263
  • [44] DISPOSITION OF DAPSONE IN MAN - INFLUENCE OF THE NAT2 AND CYP2C9 GENETIC POLYMORPHISMS
    Scheuch, E.
    Wegner, D.
    Modess, C.
    Paulick, A.
    Nassif, A.
    Oswald, S.
    Siegmund, W.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 : 11 - 11
  • [45] Association of CYP2C9 polymorphism to cyclophosphamide kinetics
    Timm, R
    Kaiser, R
    Sezer, O
    Roots, I
    Kroemer, HK
    Cascorbi, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2002, 365 : R116 - R116
  • [46] Effect of 7-hydroxyflavone and fluconazole on the CYP450-2C9 mediated metabolism of ibuprofen
    Lauterbach, Emily M.
    Fish, Daryle
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [47] Influence of azimilide on CYP2C19-mediated metabolism
    El Mouelhi, M
    Worley, DJ
    Kuzmak, B
    Destefano, AJ
    Thompson, GA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (04): : 373 - 378
  • [48] Simultaneous determination of fluoxetine and norfluoxetine enantiomers using isotope discrimination mass spectroscopy solution method and its application in the CYP2C9-mediated stereoselective interactions
    Yu, Lushan
    Wang, Shengjia
    Jiang, Huidi
    Zhou, Hui
    Zeng, Su
    JOURNAL OF CHROMATOGRAPHY A, 2012, 1236 : 97 - 104
  • [49] Metabolic activation of aegeline mediated by CYP2C19
    Tian, Min
    Zhou, Shenzhi
    Li, Wei
    Li, Jiaru
    Yang, Lan
    Peng, Ying
    Zheng, Jiang
    XENOBIOTICA, 2021, 51 (11) : 1217 - 1228
  • [50] Effect of iguratimod on diclofenac metabolism by CYP2C9 in rats and human recombinant CYP2C9 yeast cells
    Usman, Muhammad
    Zhen-Han, Zhu
    Ze-Na, Chang
    Jun-Ping, Han
    Wen, Qian
    Chang-Qing, Yang
    Miyu, Nishikawa
    Toshiyuki, Sakaki
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 55